Ask an Expert: Efficient Development of Gene Therapy and Vaccines Through Comprehensive Viral Vector Characterization Webinar

Back

Ever-more structurally complex bio-molecules and biological entities are coming into focus within the pharma development space, with fit-for-purpose analytics becoming more important to their success. Reducing development time and optimising formulation through applying orthogonal analytical technologies is key to bringing them to market in an efficient, risk-free manner.

Date recorded: June 22, 2021

In addition to synthetic nanoparticles, viral capsids are also increasingly used as vectors in gene therapy and vaccines (such as those used in the Covid-19 pandemic). These include the lentivirus, rAAV and Adenovirus vectors.

In order to develop efficient virally-vectored therapies produced through controlled and economical manufacturing processes, multiple challenges need to be addressed. These range from capsid design through to identification of optimal process and formulation conditions to comprehensive quality control of Drug Substance and Drug Product.

Addressing these challenges require extensive characterization including measurements of capsid size & count, % full, aggregate formation, stability, genome release and capsid charge.

In this webinar, Michael Caves will demonstrate how Dynamic Light Scattering, Differential Scanning Calorimetry, nanoparticle tracking analysis (NTA) and multi-detection SEC (SEC-MALS) can be used orthogonally to optimise the efficiency of gene therapy development and ensure such products are bought to market as quickly and affordably as possible. This webinar is part of Malvern Panalytical's "Ask an Expert" series on gene therapy and other viral vectors. Scroll down for more.